Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vigil Neuroscience
Biotech
Analysts 'highly encouraged' by Vigil's phase 1 Alzheimer's data
The early clinical data position Vigil to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival antibody.
Nick Paul Taylor
Jan 23, 2025 9:51am
FDA greenlights Vigil's Alzheimer's trial—with a partial hold
Sep 11, 2023 12:00pm
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Roche's executive dominoes continue to tip—Chutes & Ladders
Dec 16, 2022 9:30am
Vigil bags $90M to take ex-Amgen CNS assets into the clinic
Aug 18, 2021 7:00am
Vigil targets 'sentinel cells' to fight neurodegeneneration
Dec 8, 2020 8:00am
